189 related articles for article (PubMed ID: 28502234)
21. Folliculogenesis Is Not Fully Inhibited during GnRH Analogues Treatment in Mice Challenging Their Efficiency to Preserve the Ovarian Reserve during Chemotherapy in This Model.
Horicks F; Van Den Steen G; Houben S; Englert Y; Demeestere I
PLoS One; 2015; 10(9):e0137164. PubMed ID: 26325271
[TBL] [Abstract][Full Text] [Related]
22. Orthotopic transplantation of cryopreserved mouse ovaries and gonadotrophin releasing hormone analogues in the restoration of function following chemotherapy-induced ovarian damage.
Li Q; Szatmary P; Liu Y; Ding Z; Zhou J; Sun Y; Luo F; Wang Y; Zhu J
PLoS One; 2015; 10(3):e0120736. PubMed ID: 25811681
[TBL] [Abstract][Full Text] [Related]
23. Targeted anti-apoptosis activity for ovarian protection against chemotherapy-induced ovarian gonadotoxicity.
Tan SJ; Lee LJ; Tzeng CR; Wang CW; Hsu MI; Chen CH
Reprod Biomed Online; 2014 Nov; 29(5):612-20. PubMed ID: 25246113
[TBL] [Abstract][Full Text] [Related]
24. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
Elgindy E; Sibai H; Abdelghani A; Mostafa M
Obstet Gynecol; 2015 Jul; 126(1):187-95. PubMed ID: 26241272
[TBL] [Abstract][Full Text] [Related]
25. Regulation of gonadotropin-releasing hormone (GnRH) receptor-I expression in the pituitary and ovary by a GnRH agonist and antagonist.
Mo Y; Peng P; Zhou R; He Z; Huang L; Yang D
Reprod Sci; 2010 Jan; 17(1):68-77. PubMed ID: 19861704
[TBL] [Abstract][Full Text] [Related]
26. Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists.
Hickman LC; Valentine LN; Falcone T
Am J Obstet Gynecol; 2016 Oct; 215(4):415-22. PubMed ID: 27422055
[TBL] [Abstract][Full Text] [Related]
27. Protective effect of dienogest on chemotherapy-induced reduced fertility in female rats.
Tsuyoshi H; Orisaka M; Fukuda S; Hattori K; Tsang BK; Yoshida Y
Steroids; 2015 Jan; 93():1-7. PubMed ID: 25449767
[TBL] [Abstract][Full Text] [Related]
28. The protective effects of gonadotropin-releasing hormone agonist on ovarian functions in breast Cancer patients receiving chemotherapy.
Wang C; Yu XF
Discov Med; 2018 Jan; 25(135):7-12. PubMed ID: 29466689
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin-releasing hormone (GnRH) analogues and the ovary: do GnRH antagonists destroy primordial follicles?
Gupta RK; Flaws JA
Fertil Steril; 2005 May; 83(5):1339-42. PubMed ID: 15866566
[TBL] [Abstract][Full Text] [Related]
30. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.
Phelan R; Mann E; Napurski C; DeFor TE; Petryk A; Miller WP; Wagner JE; Verneris MR; Smith AR
Bone Marrow Transplant; 2016 Oct; 51(10):1369-1375. PubMed ID: 27272448
[TBL] [Abstract][Full Text] [Related]
31. GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation.
Valsamakis G; Valtetsiotis K; Charmandari E; Lambrinoudaki I; Vlahos NF
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216409
[TBL] [Abstract][Full Text] [Related]
32. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
Blumenfeld Z; Evron A
Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
[TBL] [Abstract][Full Text] [Related]
33. Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats.
Yeh J; Kim BS; Peresie J
Am J Obstet Gynecol; 2008 Apr; 198(4):463.e1-6; discussion 463.e6-7. PubMed ID: 18395042
[TBL] [Abstract][Full Text] [Related]
34. mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy.
Goldman KN; Chenette D; Arju R; Duncan FE; Keefe DL; Grifo JA; Schneider RJ
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3186-3191. PubMed ID: 28270607
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic ovarian preservation in young women undergoing chemotherapy.
Chahvar ST; Al-Shawaf T; Tranquilli AL
Curr Med Chem; 2014; 21(2):223-9. PubMed ID: 24164203
[TBL] [Abstract][Full Text] [Related]
36. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
37. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
38. Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide.
Lemos CN; Reis FM; Pena GN; Silveira LC; Camargos AF
Reprod Biol Endocrinol; 2010 May; 8():51. PubMed ID: 20482803
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin-releasing hormone agonist affects rat ovarian follicle development by interfering with FSH and growth factors on the prevention of apoptosis.
Parborell F; Dain L; Tesone M
Mol Reprod Dev; 2001 Oct; 60(2):241-7. PubMed ID: 11553925
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.
Meyer L; Murphy LA; Gumer A; Reichman DE; Rosenwaks Z; Cholst IN
Fertil Steril; 2015 Sep; 104(3):637-42. PubMed ID: 26149355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
